This is the first longitudinal study of immune profiles and autologous hematopoietic cell transplant (AHCT) survival in Bcell non-Hodgkin lymphoma (B-NHL) patients and the effect of plerixafor mobilization on immune reconstitution in this population. A comprehensive immunophenotyping panel was performed in 104 consecutive adult B-NHL patients (58% diffuse large B cell and 42% mantle cell) who received AHCT (1/2008-11/2014), at a median of 28 days pre-AHCT (N = 104) and Day +100 (N = 83) post-AHCT. Median follow-up post-AHCT was 61 months (range: 8-120 months). Compared to patients mobilized with filgrastim and plerixafor, patients mobilized with filgrastim alone had a higher proportion of CD4 + naïve (p = 0.006) and CD8+ central memory T-cells (p = 0.006) pre-AHCT. For patients transplanted in complete remission (CR), a higher proportion of CD8+ effector memory T-cells pre-AHCT was associated with worse progressionfree survival (PFS; p < 0.01) and overall survival (OS; p < 0.01). A higher ratio of CD8:CD4+ central memory T-cells pre-AHCT was associated with worse PFS (p < 0.0001) and OS (p = 0.0034). This same ratio measured post-AHCT among patients in CR on Day +100 was associated with worse and OS (p = 0.008) but not PFS (p = not significant). These immune subsets are complementary biomarkers which identify patients transplanted in CR who have poor survival prognoses and may warrant further clinical interventions.
Introduction
Autologous hematopoietic cell transplant (AHCT) plays an important role in the treatment of B-cell non-Hodgkin lymphoma (B-NHL), including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), both in the upfront and relapsed/refractory settings [1] . In addition to patient and disease-related factors such as age [2] , Charlson comorbidity index [3] , disease status pre-AHCT [4] , international prognostic index (IPI) score at AHCT [5] and high-dose regimen [6] , composition of the infused cell product (dendritic cell content [7] and lymphocyte to monocyte ratio [8] ), and immune reconstitution [9] after AHCT have recently emerged as independent predictors of AHCT survival in B-NHL.
The majority of these prognostic factors was evaluated before the introduction of plerixafor for hematopoietic cell mobilization and should be reexamined to determine if they retain their relevance in the plerixafor era. Specifically, plerixafor-mobilized grafts have different characteristics compared with those obtained with filgrastim (also known as granulocyte colony stimulating factor) alone [10, 11] . For example, contrary to a previous study conducted in patients mobilized with filgrastim alone [12] , patients mobilized with plerixafor/filgrastim demonstrated an association between CD34+ stem cell dose and better long-term platelet recovery after AHCT, but this did not correlate with time to initial neutrophil or platelet engraftment, long-term neutrophil or hemoglobin recovery, or overall survival (OS) [13] .
We report the first study of peripheral blood immune cell subsets in patients before and after AHCT with recovery patterns and AHCT survival in B-NHL patients mobilized with or without plerixafor. We hypothesized that a more detailed analysis of peripheral blood subpopulations beyond absolute lymphocyte count (ALC) would identify phenotypes associated with shorter survival after AHCT. Subpopulations of T cells, natural killer cells, B cells, and dendritic cells of B-NHL patients prior to and at Day +100 AHCT were examined.
This study aimed to (1) investigate whether previously described patient and disease-related factors retain their association with survival in patients mobilized with plerixafor-containing regimens, (2) compare immunological recovery and survival in patients mobilized with filgrastim alone versus filgrastim and plerixafor, and (3) identify patterns of immune recovery associated with progression-free survival (PFS) and OS to identify patients with poor prognosis who may benefit from alternative or additional therapies.
Methods

Patient population
This is a retrospective cohort comprised of 104 consecutive adult (≥18 years) B-NHL patients (DLBCL 58%, and MCL 42%) who received AHCT at Roswell Park Comprehensive Cancer Center between 1/2008 and 11/2014 (Supplemental Fig. 1 ). Approval for the review of these records was obtained from the Roswell Park Institutional Review Board and research was performed in accordance with the Declaration of Helsinki.
Patients' therapy was clinically determined by age and comorbidities. Specifically, patients <60 years received VCB (n = 48; etoposide 2.4 g/m 2 continuous infusion over 30 h starting on Day 8, cyclophosphamide 1800 mg/m 2 daily for four doses starting on Day 7, carmustine 600 mg/m 2 on Day 3) [14] . Patients ≥60 years or those <60 years who had a high HCT-CI score received BuCy (n = 56; busulfan 0.8 mg/kg (pharmacokinetically dosed to a target level of 750 ng/ml steady state level) every 6 h for 16 doses starting on Day 7 and cyclophosphamide 60 mg/kg daily for two doses starting on Day 3).
Mobilization and collection of hematopoietic cells
Upfront plerixafor-based mobilization was instituted in all B-NHL patients in April of 2010 in order to improve hematopoietic cell mobilization and collection efficiency. Therefore, mobilization regimens in B-NHL patients included either (1) filgrastim 10 μg/kg/day alone (prior to 4/ 2010) or (2) filgrastim 10 μg/kg/day for at least 4 days followed by plerixafor 0.24 mg/kg/daily administered on the day prior to start of mobilization (after 4/2010).
Filgrastim was given daily until the white blood cell count reached 8000 × 10 9 /l at which time apheresis commenced. Filgrastim ± plerixafor were continued during daily apheresis collection per standard protocol until the prescribed dose of CD34+ cells/kg was obtained. All patients underwent a minimum of 2 days of hematopoietic cell collection and received unmanipulated, peripheral blood-derived hematopoietic cells for AHCT.
Immune profiles were tested pre-and post-AHCT on Day +100 to assess for consistency, potential effect of AHCT on immune profile and to determine the most relevant time point which is associated with PFS/OS.
Flow cytometric analysis
A comprehensive immunophenotyping panel was performed blinded to treatment and outcome at a median of 28 days pre-AHCT (N = 104) and at Day+ 100 post-AHCT (N = 83), via methods previously described [15] . Blood for flow cytometric studies was drawn into heparinized tubes and processed by the laboratory within 24 h of collection. Briefly, blood was washed three times with flow cytometry buffer (0.5% BSA, 0.04 g/l Na 2 EDTA, and 0.1% sodium azide in PBS pH 7.2) and immunophenotyped using a stainand-then-lyse technique. Data acquisition was performed on a FACSCanto II flow cytometer (Becton Dickinson Biosciences, San Jose, CA, USA) controlled daily using cytometer, setup, and tracking beads. For the peripheral blood phenotyping, 50,000 events were acquired for each of the determinations. Data were analyzed using WinList version 6 (Verity Software House, Topsham, ME). The comprehensive flow cytometry strategy to identify the different lymphoid subsets is shown in Table 1 .
Statistical analysis
Univariate analyses of patient and clinical characteristics were conducted using Pearson χ 2 test or Fisher's exact text for categorical variables, and Wilcoxon two-sample test or Kruskal-Wallis one-way test for continuous variables, as appropriate. All box-and-whisker plots can be interpreted as the median dividing the box in half with the lower edge of the box as the 25th percentile and the upper edge of the box as the 75th percentile. Any dots outside the minimum and maximum (the "whiskers") are considered outliers. OS was calculated from the date of AHCT (Day 0, infusion of hematopoietic cells) to the date of death due to any cause with patients censored at last follow-up. PFS was calculated from the date of AHCT to the date of first disease progression/relapse or death due to any cause; patients were censored at the last follow-up in the absence of disease progression/relapse. Early ALC recovery was defined as >500 lymphocytes/μl (by peripheral blood differential count) by Day +15 post-AHCT. Cell marker categories were predefined as >25%, 25-75%, and <75% of the absolute count for each cell type; these categories were then collapsed based on data frequencies. Analyses on immune cell markers pre-AHCT were conducted among patients who were in complete remission (CR) at the time of transplant (n = 76), whereas post-AHCT analyses were conducted among patients who were in CR at Day +100 (n = 71). Kaplan-Meier survival curves were constructed and significance was tested using the log-rank statistic with results shown as p-values. Multiple comparisons were considered in the setting of a small sample size, with p < 0.01 set as the statistical significance threshold. All statistical analyses were two sided and performed using SAS v9.4 (SAS Institute, Cary, CA) and analytic figures were created using SPSS v21.0 (SPSS Inc., Chicago, IL) and R v3.3.2 (R Core Team, Vienna, Austria). Sensitivity analyses were conducted to assess if differences existed between DLBCL and MCL pre-and post-AHCT; since no substantial differences existed, all analyses were conducted using the full dataset.
Results
Clinical characteristics and correlation with survival in all B-NHL patients
Baseline characteristics of all 104 patients pre-AHCT and the 76 patients in CR are reported in Table 2 . Median follow-up was 61 months (range: 8-120 months) with no patients lost to follow-up. In all 104 patients, 2 patients died of infection (both before 1-year post-AHCT), 4 patients died of second cancers (1 AML, 2 MDS, 1 lung cancer, and all diagnosed between 2 and 3 years post-AHCT) and 30 patients died of disease relapse (71% of all deaths). For patients in CR pre-AHCT, the median CD34+ cell dose infused was 4.79 × 10 6 /kg (range: 1.64-197.5 × 10 6 /kg), and median ALC dose infused was 0.81 × 10 9 /kg (range: 0-2.48 × 10 9 /kg). Patients who received plerixafor were more likely to be in CR pre-AHCT (p < 0.01; Table 2 ), which is probably a consequence of the sequential nature of the two cohorts and better patient selection for transplant.
Most MCL patients were transplanted in CR1 (77%). Of the DLBCL patients, 25% were transplanted in CR1 (due to high-risk features including double or triple hit, two inductions to achieve CR1, transformed from low-grade . There were no substantial baseline differences between all patients and those patients in CR; therefore, because of a significant difference in OS by disease status pre-AHCT (p = 0.005; Supplemental Fig. 2 ), the subset of 76 patients in CR at time of AHCT are reported for the pre-AHCT for the remainder of the results. Post-AHCT results are reported among those patients who were in CR at Day +100 (n = 71).
Effect of plerixafor on immune recovery
Baseline immunophenotyping data were available in all patients, while Day +100 immunophenotyping data were available in 82% (n = 62/76) of patients in CR pre-AHCT. Time to platelet and neutrophil recovery was not associated with plerixafor use (data not shown). In comparison to patients mobilized with plerixafor/filgrastim, patients mobilized with filgrastim alone had similar proportions of immune cells (Supplemental Fig. 3) , and PFS and OS did not significantly differ by plerixafor use (Supplemental Fig. 4 ), NHL histology, age, Karnofsky performance status, body mass index, or high-dose regimen.
Relative numbers of immune cells and correlation with survival
PFS and OS were significantly associated with specific immune cell populations. Prior to AHCT, higher levels of CD8+ EM T cells (>75%; Fig. 1 ) conveyed worse PFS (p = 0.0088) and OS (p = 0.023) than those at lower levels (≤75%), although this was not statistically significant for OS. This association did not persist when CD8+ EM T cells were measured for patients in CR at Day +100 post-AHCT ( Fig. 2 ; PFS: p = not significant (NS), OS: p = 0.052) nor did it exist if a different threshold of CD8+ EM T cells were used (≥25% versus <25%; PFS: p = NS; OS: p = 0.056; Supplemental Fig. 5 ). There was no significant difference in PFS or OS between patients who had a higher proportion of CD8+ CM T cells or CD4+ EM T-cells pre-AHCT or at Day +100 post-AHCT in comparison to those that had a lower proportion (≤ 75%) (Supplemental Figs. 6 and 7, respectively). In these B-NHL patients who had received prior B-cell depleting therapy (primarily rituximab), total CD19+ and CD20+ B cells were near absent when measured at both the pre-AHCT and Day +100 AHCT timepoints. Therefore B-cell subsets could not be analyzed in relation to any outcomes. NK cells and dendritic cells (defined in Table 1) were not associated with any outcomes when measured at either pre-AHCT or Day +100 post-AHCT (data not shown). No difference in survival existed by chemotherapy type (DLBCL: RDHAC/P versus R/OICE versus other; MCL: RCHOP versus RHyperCVAD versus other) nor was there a difference in reported immune cell phenotypes by last chemotherapy regimen pre-AHCT (data not shown). In addition, there was no difference in survival by the number of lines of therapy (1-2 versus ≥3 lines) among 
Relative ratios of immune cells and correlation with survival
Relative proportions of immune cell subsets measured pre-AHCT were also prognostic of PFS and OS (Fig. 3) . A higher ratio of CD8:CD4+ CM T cells was significantly associated with worse PFS (p < 0.0001) and OS (p = 0.0034), with similar results for a higher ratio of CD8:CD4+ EM T cells (PFS: p = 0.028, and OS: p = 0.014). No difference was seen for the ratio of CD8+ EM:CD4+ Tregs (PFS: p = NS, and OS: p = NS). Similar results were found for the relative ratios of immune cell subsets measured for patients in CR at Day +100 post-AHCT ( Fig. 4) . Among patients who were in CR at Day +100, a lower ratio of CD8:CD4+ CM T cells did not have a statistically significantly different PFS (p = NS) but had a significantly better OS (p = 0.0080). Despite a similar rate of progression, these patients were less likely to die from their disease than those with a higher CD8:CD4 CM T-cell ratio (Fig. 4a ).The relative proportions of CD8: CD4+ EM T cells ( Fig. 4b ) and CD8+ EM:CD4+ Tregs (Fig. 4c ) measured at Day +100 post-AHCT were not associated with PFS or OS.
Discussion
This is the first study to investigate patterns of immune cell subsets before and after AHCT which may be associated with survival in patients with DLBCL and MCL. We report that previously published patient-and disease-related prognostic factors are not validated in this cohort of patients mobilized with plerixafor-containing regimens, with the sole exception of disease status (in CR) at time of AHCT. Hence, our immunophenotype analyses focused on patients in CR at time of AHCT and found several new prognostic biomarkers of long-term PFS and OS (Supplemental Fig. 8 ).
While we confirm that patients transplanted in CR have longer PFS and OS [4] , we did not find confirm prior reports of significant associations with OS or PFS for age [2] , IPI [5] , or high-dose regimen [6] . It is unknown if this is due to better patient selection, use of plerixafor for mobilization or lack of statistical power. It is worth noting that although patients in the plerixafor group were older, there were no differences in CR, PFS, or OS between the two mobilization groups. In addition, there was no difference in immune cell subsets pre-AHCT by mobilization agent. These immune cell subsets were associated with survival independent of the mobilization agents assessed.
The immune system has been an area of interest for understanding control of B-NHL and other malignancies. In the setting of B-NHL patients uniformly treated with B-cell depleting therapy (confirmed by near absent numbers of B cells in the samples tested, data not shown), the focus of this study was on the impact of various T cell, Natural Killer cell, and dendritic cell subsets on antitumor responses. While we did not find any significant impact of NK or dendritic cells on PFS/OS, we do report novel associations of T-cell subsets and ratios which convey poor prognosis in patients in CR at time of AHCT. Our results demonstrating higher CD8+ CM T cells with worse survival after AHCT contrasts with a prior report in allogeneic HCT patients indicating specificity of T-cell subsets by treatment [16] . Interestingly, the similar results between pre-and post-AHCT suggest either time point can be measured as a biomarker for long-term disease control and survival. The primary effect could be (1) patient biology or (2) patient response to treatment, although we did not find a difference by therapy, which may be explained by the temporary effects of cyclophosphamide on T cells in comparison to the more prolonged effects of rituximab on B cells. In addition, our previous study using the same immunophenotype panel after AHCT for multiple myeloma found higher γδ T cells were associated with improved PFS and OS with no significant findings for the T-cell subsets reported in our study of B-NHL [15] . Taken together, this growing literature supports the specificity of T-cell subsets by underlying malignancy and treatment which advocates for study designs focused on single disease/treatment combinations. Alternatively, the specific impact of CD8+ CM T cells on survival may be related to differential antigen thresholds for recall proliferation between naïve and memory CD8+ T cells, which varies by disease [17] .
Of the patients who achieved a CR at Day +100, those with a lower ratio of CD8:CD4+ CM T cells did not have at significantly different rate of relapse from those who had a higher ratio, but they were able to be salvaged and had a better OS. A higher ratio of CD8:4+ CM T cells will have a poorer prognosis and possibly can be targeted for adjuvant strategies for relapse (consolidation/maintenance). Conversely, patients with a lower ratio of CD8:4+ CM T cells do well suggesting this is a useful biomarker after outcome. Our finding that a higher ratio of CD8:CD4+ CM T cells was associated with worse survival is in contrast to prior reports in solid tumor patients where a higher ratio was associated with a favorable prognosis [18, 19] . This also seems counter-intuitive to what is known about antitumor immunity. However, T-cell exhaustion, which was not measured by our immunophenotyping panel, is a likely explanation [20] . In the setting of chronic viral infection, higher numbers of CD8+ T cells that have lost their effector functionality is associated with CD4+ T-cell deficiency [21] . Similarly, studies of adoptive T-cell transfer to generate antitumor responses have discovered a role in T-cell exhaustion leading to disease relapses after an initial favorable response [22, 23] . This is the first longitudinal study of the impact of immune profiles on AHCT survival in B-NHL patients in the plerixafor era. In otherwise favorable risk patients transplanted in CR, we were able to distinguish novel immune cell biomarkers to define patients with poor prognosis. Additional studies are needed to further classify these immune profiles into clinically actionable subgroups in order to improve the success of AHCT for B-NHL and to investigate the relevance of these findings in the setting of chimeric antigen receptor T-cell therapy for B-NHL.
